A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18–47.

Article  PubMed  PubMed Central  Google Scholar 

Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54:1900161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–87.

Article  CAS  PubMed  Google Scholar 

Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.

Article  PubMed  Google Scholar 

Maher TM, Stowasser S, Nishioka Y, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019;7:771–9.

Article  CAS  PubMed  Google Scholar 

Lancaster L, Goldin J, Trampisch M, et al. Effects of nintedanib on quantitative lung fibrosis score in idiopathic pulmonary fibrosis. Open Respir Med J. 2020;14:22–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015;16:116.

Article  PubMed  PubMed Central  Google Scholar 

Kolb M, Raghu G, Wells AU, et al. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2018;379:1722–31.

Article  CAS  PubMed  Google Scholar 

Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197:356–63.

Article  CAS  PubMed  Google Scholar 

Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7:60–8.

Article  CAS  PubMed  Google Scholar 

Lancaster L, Crestani B, Hernandez P, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6: e000397.

Article  PubMed  PubMed Central  Google Scholar 

Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol. 1998;45:427–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Food and Drug Administration. Guidance for Industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment, 2005. https://www.fda.gov/media/71546/download. Accessed 1 Apr 2022.

Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763–74.

Article  PubMed  PubMed Central  Google Scholar 

Lasky JA, Criner GJ, Lazarus HM, et al. Safety of nintedanib in patients with idiopathic pulmonary fibrosis: global pharmacovigilance data. Adv Ther. 2020;37:4209–19.

Article  CAS  PubMed  Google Scholar 

Bonella F, Kreuter M, Hagmeyer L, et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration. 2016;92:98–106.

Article  CAS  PubMed  Google Scholar 

Hughes G, Toellner H, Morris H, et al. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med. 2016;5:78.

Article  PubMed  PubMed Central  Google Scholar 

Toellner H, Hughes G, Beswick W, et al. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clin Transl Med. 2017;6:41.

Article  PubMed  PubMed Central  Google Scholar 

Brunnemer E, Wälscher J, Tenenbaum S, et al. Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis. Respiration. 2018;95:301–9.

Article  CAS  PubMed  Google Scholar 

Fletcher SV, Jones MG, Renzoni EA, et al. Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Res. 2018;4:00049–2018.

Article  PubMed  PubMed Central  Google Scholar 

Tzouvelekis A, Karampitsakos T, Kontou M, et al. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study in Greece. Pulm Pharmacol Ther. 2018;49:61–6.

Article  CAS  PubMed  Google Scholar 

Yoon HY, Park S, Kim DS, et al. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. Respir Res. 2018;19:203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bargagli E, Piccioli C, Rosi E, et al. Pirfenidone and nintedanib in idiopathic pulmonary fibrosis: real-life experience in an Italian referral centre. Pulmonology. 2019;25:149–53.

Article  CAS  PubMed  Google Scholar 

Cerri S, Monari M, Guerrieri A, et al. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a 24-month assessment. Respir Med. 2019;159:105803.

Article  PubMed  Google Scholar 

Kato M, Sasaki S, Nakamura T, et al. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci Rep. 2019;9:12062 (Author correction: Sci Rep. 2020;10:12080).

Article  PubMed  PubMed Central  Google Scholar 

Pereira CAC, Baddini-Martinez JA, Baldi BG, et al. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil. J Bras Pneumol. 2019;45: e20180414.

Article  PubMed  PubMed Central  Google Scholar 

Antoniou K, Markopoulou K, Tzouvelekis A, et al. Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Res. 2020;6:00172–2019.

Article  PubMed  PubMed Central  Google Scholar 

Cameli P, Refini RM, Bergantini L, et al. Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study. Front Mol Biosci. 2020;7: 581828.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Senoo S, Miyahara N, Taniguchi A, et al. Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤50%: a multi-center retrospective analysis. PLoS ONE. 2020;15: e0236935.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takeda T, Kunimatsu Y, Tani N, et al. Improvement in subjective symptoms and tolerability in response to nintedanib treatment in elderly patients with idiopathic pulmonary fibrosis. J Clin Med. 2020;9:755.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vianello A, Salton F, Molena B, et al. Nintedanib treatment for idiopathic pulmonary fibrosis patients who have been switched from pirfenidone therapy: a retrospective case series study. J Clin Med. 2020;9:422.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato M, Sasaki S, Tateyama M, et al. Clinical significance of continuable treatment with nintedanib over 12 months for idiopathic pulmonary fibrosis in a real-world setting. Drug Des Devel Ther. 2021;15:223–30.

Article  PubMed  PubMed Central  Google Scholar 

Noor S, Nawaz S, Chaudhuri N. Real-world study analysing progression and survival of patients with idiopathic pulmonary fibrosis with preserved lung function on antifibrotic treatment. Adv Ther. 2021;38:268–77.

Article  CAS  PubMed  Google Scholar 

Wright WA, Crowley LE, Parekh D, et al. Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2021;8: e000782.

Article  PubMed  PubMed Central  Google Scholar 

Harari S, Pesci A, Albera C, et al. Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study. Respiration. 2022;101(6):577–84.

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif